Momelotinib, sold under the brand name Ojjaara, is an anticancer medication used for the treatment of myelofibrosis.

It is a Janus kinase inhibitor and it is taken by mouth.

The most common adverse reactions include dizziness, fatigue, bacterial infection, hemorrhage, thrombocytopenia, diarrhea, and nausea.

Momelotinib is indicated for the treatment of intermediate or high-risk myelofibrosis in adults with anemia.

It is intended for the treatment of disease-related splenomegaly or symptoms in adults with moderate-to-severe anemia who have primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis.

Leave a Reply

Your email address will not be published. Required fields are marked *